C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects

被引:67
作者
Min, DI [1 ]
Ellingrod, VL [1 ]
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
关键词
MDR1 gene mutation; P-glycoprotein; cyclosporine; pharmacokinetics;
D O I
10.1097/00007691-200206000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects, Blood cyclosporine concentrations were measured by HPLC. Concentration-time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous Cl, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean t(max) 1.6+/-0.3 hours, mean C-max 1337+/-329 ng/mL, mean Cl/F 66.5+/-18.3 L/h, and mean AUC 5642+/-1577 ng.h/mL in C1/F group and mean t(max) 2.0+/-0.6 hours, mean C-max 1540+/-721 ng/mL, mean Cl/F 55.2+/-18.9 L/h, and mean AUC 6902+/-1405 ng.h/mL in C/T+T/T group. Although C-max and AUC in C/T and T/T group were 15% and 227c larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 25 条
[1]  
DELANNOY IAM, 1992, BIOCH RES COMMUN, V30, P551
[2]  
First MR, 1996, CLIN TRANSPLANT, V10, P55
[3]   Inhibition of P-glycoprotein-mediated drug transport - A unifying mechanism to explain the interaction between digoxin and quinidine [J].
Fromm, MF ;
Kim, RB ;
Stein, CM ;
Wilkinson, GR ;
Roden, DM .
CIRCULATION, 1999, 99 (04) :552-557
[4]  
GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97
[5]  
GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019
[6]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[7]   Is it sex or is it gender? [J].
Kim, JS ;
Nafziger, AN .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) :1-3
[8]  
Kim RB, 1999, PHARMACEUT RES, V16, P408
[9]   Identification of functionally variant MDR1 alleles among European Americans and African Americans [J].
Kim, RB ;
Leake, BF ;
Choo, EF ;
Dresser, GK ;
Kubba, SV ;
Schwarz, UI ;
Taylor, A ;
Xie, HG ;
McKinsey, J ;
Zhou, S ;
Lan, LB ;
Schuetz, JD ;
Schuetz, EG ;
Wilkinson, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) :189-199
[10]   CYCLOSPORINE METABOLISM IN HUMAN-LIVER - IDENTIFICATION OF A CYTOCHROME-P-450III GENE FAMILY AS THE MAJOR CYCLOSPORINE-METABOLIZING ENZYME EXPLAINS INTERACTIONS OF CYCLOSPORINE WITH OTHER DRUGS [J].
KRONBACH, T ;
FISCHER, V ;
MEYER, UA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 43 (06) :630-635